Opendata, web and dolomites

PNEUMOSIP SIGNED

PNEUMOSIP

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PNEUMOSIP project word cloud

Explore the words cloud of the PNEUMOSIP project. It provides you a very rough idea of what is the project "PNEUMOSIP" about.

antibiotic    infectious    rapid    infected    2012    simplicity    mainstream    cap    healthy    elderly    time    device    children    host    influenzae    haemophilus    aetiology    standard    market    antibiotics    quantitative    nasopharynx    valued    precision    populations    automated    treatment    population    laboratory    hours    adult    diagnostic    discarded    arrival    concretely    bacteria    identification    colonizer    analysing    first    relationship    respiratory    fast    patient    agents    appropriate    streptococcus    segment    empiric    clinicians    hib    detection    death    compact    fourth    pneumoniae    virus    diagnose    rsv    70    community    faster    responsible    complication    poct    accurate    causal    useless    hospital    pneumonia    guidelines    tests    syncytial    treatments    acquired    diagnosing    world    starting    diseases    pathogens    child    aetiological       million    pneumosip    415    administration    acts    combine    slowness    resistances    disease    poc    therapy   

Project "PNEUMOSIP" data sheet

The following table provides information about the project.

Coordinator
LABORATORIOS ALPHA SAN IGNACIO PHARMA S.L. - ALPHASIP 

Organization address
address: CALLE CERVANTES 40 - 3P - PC
city: ZARAGOZA
postcode: 50006
website: www.alphasip.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.pneumosipdx.com
 Total cost 3˙389˙912 €
 EC max contribution 3˙389˙912 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LABORATORIOS ALPHA SAN IGNACIO PHARMA S.L. - ALPHASIP ES (ZARAGOZA) coordinator 3˙389˙912.00

Map

 Project objective

PneumoSIP project aims to be the first fully automated device in the POC market for the fast quantitative aetiological diagnose of Community-Acquired Pneumonia (CAP) also analysing antibiotic resistances to enable the most appropriate treatment for each infected patient. CAP is known to affect about 1/1,000 of the adult population per year, being even higher in the elderly and children populations. It is the fourth case of death in the world, and the leading cause of death in child population under 5 years old. The causal relationship between pathogens and pneumonia has been clearly established, being Streptococcus pneumoniae, Haemophilus influenzae type b (Hib) and the respiratory syncytial virus (RSV) the main pathogens responsible for CAP in Europe. Antibiotic therapy is the mainstream treatment for CAP, and the appropriate treatment involves starting empiric antibiotics administration within 8 hours of hospital arrival. Given this time constrain, traditional methods for diagnosing the aetiology of CAP have been discarded for CAP guidelines due to the slowness in sample to results. Another complication is that S. pneumoniae is a common colonizer of the nasopharynx (up to 70% of healthy population acts as a host), making the simple detection of the bacteria a useless diagnostic method. Thus, clinicians need rapid and accurate quantitative tests capable of identifying infectious agents and their potential antibiotic resistances. Therefore, PneumoSIP project aims to be a compact Respiratory Infectious Diseases diagnostic device providing fast quantitative identification of pathogens involved in CAP, enabling faster and more specific treatments. PneumoSIP seeks to combine laboratory standard precision with the simplicity required for POC applications. The market for PneumoSIP system is the POC market, concretely the Infectious Disease POC testing segment. The POCT segment was valued at $415.4 million in 2012 where Pneumosip will greatly impact.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PNEUMOSIP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PNEUMOSIP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.;H2020-EU.3.1.3.)

FETAL MONITORING (2016)

Safe and accurate fetal monitoring

Read More  

PReDicT (2015)

Predicting Response to Depression Treatment

Read More  

MPIPETrace (2015)

Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.

Read More